Fundraising FoxPalo Santo VC — Full Portfolio
30 tracked investments · listed companies and verified rows first
2AB BioscienceS develops first-in-class small molecule therapeutics targeting the 5-HT2A receptor for ophthalmology and central nervous system disorders.
BiotechDeep TechDigital HealthEdTechHealthtechMedical DevicesSanta Monica, US
Alex Speiser(Co-Founder & Chief Executive Officer)inCharles Nichols, PhD(Co-Founder & Chief Science Officer)David Nichols, PhD(Co-Founder & Head of Chemistry)Tim Foster, PhD(Co-Founder & Head of Translational Discovery)
BoardGopal Das(Director)
Co-investorsLIONHEART VENTURESWhat If Ventures
AtaiBeckley develops rapid-acting and durable mental health treatments for patients with difficult-to-treat mental health conditions.
BiotechMedical DevicesMental Health
Christian AngermayerCosmo Feilding Mellen(Founder)inSrinivas Rao
Co-investorsFJ LabsIter InvestmentsLeafy TunnelNoeticRedbus VenturesWhat If Ventures+1 more
BRC Therapeutics develops and manufactures botanically-derived pharmaceutical products, with expertise spanning drug development and manufacturing for pharmaceutical applications.
BiotechDigital HealthHealthtechMedical Devices
George Hodgin(Founder and CEO)inCharles Schumacher
Co-investorsDelta Emerald Ventures
Bright Minds Biosciences develops selective serotonin receptor agonists (5-HT2A and 5-HT2C) without 5-HT2B activity, built on a proprietary chemistry platform.
BiotechDeep TechHealthtechNew York, US
Alan Kozikowski(Executive Officer, Director)inIan McDonaldRyan Cheung(Chief Financial Officer)JAN PEDERSEN(Chief Science Officer)Gideon Shapiro(Executive Officer)Revati Sheeniwas(Executive Officer)
Co-investorsLifeSci Venture PartnersPsyMed Ventures
Delix Therapeutics develops third-generation, non-hallucinogenic neuroplastogens for people with neurological conditions, using a discovery platform to identify novel compounds.
BiotechDigital HealthMedical Devices
Co-investorsArtis VenturesCasa Verde CapitalDolby Family VenturesNoeticOMX VenturesPsyMed Ventures+6 more
Diamond Therapeutics is a preclinical biotechnology company developing drug treatments for psychiatric and neurological disorders, with a focus on the pharmacology and therapeutic use of psychedelic compounds.
BiotechHealthtechMental HealthToronto, CA
Judy Blumstock(Chief Executive Officer, Founder, Director)inMichael B. McDonnell(Chief Medical Officer)Grant McCutcheon(Chief Financial Officer)in
Co-investorsJLSNoeticNew Enterprise Associates (NEA)Nextech InvestRA Capital
Fauna Bio applies AI and computational analysis to its proprietary biobank of data from extreme mammals such as hibernating species to identify drug targets that are conserved across species including humans.
AI & Machine LearningBiotechDeep TechHealthtechEmeryville, US
Linda Goodman(Founder)inAshley(CEO)
Co-investorsage1Farvatn VentureGRIDS CapitalLifeforce CapitalMetaplanetVibe Capital+4 more
Gilgamesh Pharmaceutical develops novel chemical entities for psychiatric disorders using medicinal chemistry and AI-powered translational platforms to design rapid-acting therapies targeting neurobiological mechanisms rather than symptom management.
AI & Machine LearningBiotechDigital HealthHealthtechNew York City, US
Jonathan Sporn(Founder)inAndrew Kruegel(Founder)inDalibor Sames(Founder)inJONATHAN SPORN(Founder)inAndrew Kruegel, Ph.D.(Executive Officer)Jonathan Sporn, M.D.(President and Chief Executive Officer)in
Co-investorsAera VCFrontera Technology VenturesFrontier Path VCJames Beshara FundJLSMagnetic Ventures+25 more
Journey Clinical provides ketamine-assisted psychotherapy (KAP) for depression, anxiety, and PTSD, partnering patients with licensed therapists and medical teams while coordinating with major insurance providers.
Digital HealthMedical DevicesMental Health
Jonathan Sabbagh(Co-founder & Executive Chairman of the Board)inMyriam Barthes(Co-founder & CEO)in
Co-investorsAble PartnersAlleyCorpCoalition OperatorsFifty YearsMantis CapitalPROOF+8 more
Kadence Bio is a clinical-stage life sciences company developing therapeutics for conditions in sexual and mental health.
BiotechDigital HealthMental Health
Active seed-stage healthcare company
Eugene, US
Nicholas Allen(Chief Executive Officer)Phillip Scripa(Chief Financial Officer and Secretary)William Shortt(Chief Operating Officer)Jan Hardorp(Director)in
Co-investorsBIP VenturesJLSre.Mind Capital
Modulate Bio develops small-molecule GABAA positive allosteric modulators to treat neurological disorders including Essential Tremor, epilepsy, and anxiety.
BiotechDeep TechHealthtechAllston, US
Dario Doller(Co-founder)inKevin Hodgetts(Founding Lab / Co-founder)inAndrew Thomson(Executive Officer, Director, Promoter)in
Co-investorsPillar VCHealthspan Capital
MycoMedica Life Sciences is a biopharmaceutical company developing psilocybin-based treatments for mental health and neurodegenerative disorders.
BiotechDigital HealthMental HealthShelton, US
Co-investorsLauder PartnersObvious Ventures
Pangea Bio develops therapies targeting central nervous system and mental health disorders by activating the TrkB receptor pathway to promote neuronal survival and synaptic plasticity.
BiotechDeep TechDigital Health
Co-investorsMetaplanetNO LABEL VENTURESSeaside VenturesVox CapitalXEIA Venture Partners
Reunion Neuroscience is a clinical-stage biopharmaceutical company developing serotonergic psychedelic therapies for mental health conditions such as postpartum depression, adjustment disorder, and generalized anxiety disorder.
BiotechDigital HealthMental HealthMorristown, US
Sahil V. Kirpekar(President and CEO)inGregory Mayes(Executive Officer, Director)Ellen Lubman(Director)Mark Pollack(Executive Officer)inNathan Bryson(Executive Officer)inMark Theeuwes(Executive Officer)in
Co-investorsFemHealth VenturesMitsui Global InvestmentMPM BioImpactNovo Holdings
Sensorium Therapeutics is a clinical-stage biotech company developing novel CNS therapies for anxiety, epilepsy, and cognitive dysfunction using its SensAI platform, which integrates AI, chemistry, and curated natural product data to identify therapeutic patterns from over 50 million biological relationships.
AI & Machine LearningBiotechDigital HealthMedford, US
Jerrold Rosenbaum(Director)inJacob Hooker(Executive Officer, Director)inPranav Tadi(Executive Officer)
BoardRyan Katz(Director)inKevin Lalande(Director)inRichard Simon(Director)
Co-investorsBonaventure Equity, LLCHatteras Venture PartnersIter InvestmentsMission BiocapitalRoute 66 VenturesService Provider Capital+2 more
Syndeio Biosciences is a synapse-focused biotech developing precision neurotherapeutics for neuropsychiatric, mental health, and cognitive disorders such as depression and Alzheimer's.
AI & Machine LearningBiotechDigital Health
Co-investorsEvolution VC PartnersTenmileCatalio Capital Management
Tactogen develops patented new chemical entities, including benzofuran-based compositions, and conducts preclinical research and publishes data on these compounds.
BiotechDeep TechHealthtech
Matthew Baggott(CEO)in
Co-investorsLeafy TunnelNoeticPsyMed Ventures10X CapitalWefunder
Transcend Therapeutics develops rapid-acting pharmaceutical treatments for neuropsychiatric diseases, including PTSD and depression, targeting patients unresponsive to current psychiatric medications.
BiotechDigital HealthMedical DevicesMental Health
Blake Mandell(Co-Founder & CEO)in
Co-investorsAlleyCorpAlpha Wave GlobalEmerald Development ManagersAlley Robotics Ventures
Wavepaths develops adaptive therapeutic music designed to support mental health and wellness practitioners in their sessions.
Digital HealthMental HealthWellness & Fitness
Mendel Kaelen(Founder & CEO)in
Co-investorsMITONReflex CapitalLIONHEART VENTURESNeo Kuma Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
<UNKNOWNatai Life SciencesBeacon BiosignalsBionomicsBlackbox BioCybinFluenceneurocarePsy TherapeuticsXylo
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.